551 related articles for article (PubMed ID: 32139878)
1. Androgen receptor variant-driven prostate cancer II: advances in laboratory investigations.
Lu C; Brown LC; Antonarakis ES; Armstrong AJ; Luo J
Prostate Cancer Prostatic Dis; 2020 Sep; 23(3):381-397. PubMed ID: 32139878
[TBL] [Abstract][Full Text] [Related]
2. Androgen receptor variant-driven prostate cancer II: advances in clinical investigation.
Brown LC; Lu C; Antonarakis ES; Luo J; Armstrong AJ
Prostate Cancer Prostatic Dis; 2020 Sep; 23(3):367-380. PubMed ID: 32094489
[TBL] [Abstract][Full Text] [Related]
3. Bruceantin targets HSP90 to overcome resistance to hormone therapy in castration-resistant prostate cancer.
Moon SJ; Jeong BC; Kim HJ; Lim JE; Kim HJ; Kwon GY; Jackman JA; Kim JH
Theranostics; 2021; 11(2):958-973. PubMed ID: 33391515
[No Abstract] [Full Text] [Related]
4. Androgen Receptor Splice Variant, AR-V7, as a Biomarker of Resistance to Androgen Axis-Targeted Therapies in Advanced Prostate Cancer.
Zhang T; Karsh LI; Nissenblatt MJ; Canfield SE
Clin Genitourin Cancer; 2020 Feb; 18(1):1-10. PubMed ID: 31653572
[TBL] [Abstract][Full Text] [Related]
5. Antibody selection influences the detection of AR-V7 in primary prostate cancer.
Kaczorowski A; Chen X; Herpel E; Merseburger AS; Kristiansen G; Bernemann C; Hohenfellner M; Cronauer MV; Duensing S
Cancer Treat Res Commun; 2020; 24():100186. PubMed ID: 32619831
[TBL] [Abstract][Full Text] [Related]
6. Development of AR-V7 as a putative treatment selection marker for metastatic castration-resistant prostate cancer.
Luo J
Asian J Androl; 2016; 18(4):580-5. PubMed ID: 27174161
[TBL] [Abstract][Full Text] [Related]
7. Androgen receptor splicing variant 7: Beyond being a constitutively active variant.
Shao C; Yu B; Liu Y
Life Sci; 2019 Oct; 234():116768. PubMed ID: 31445027
[TBL] [Abstract][Full Text] [Related]
8. Molecular Origin, Expression Regulation, and Biological Function of Androgen Receptor Splicing Variant 7 in Prostate Cancer.
Chen Y; Lan T
Urol Int; 2021; 105(5-6):337-353. PubMed ID: 32957106
[TBL] [Abstract][Full Text] [Related]
9. Cotargeting Androgen Receptor Splice Variants and mTOR Signaling Pathway for the Treatment of Castration-Resistant Prostate Cancer.
Kato M; Banuelos CA; Imamura Y; Leung JK; Caley DP; Wang J; Mawji NR; Sadar MD
Clin Cancer Res; 2016 Jun; 22(11):2744-54. PubMed ID: 26712685
[TBL] [Abstract][Full Text] [Related]
10. Expression of AR-V7 and ARv
Tagawa ST; Antonarakis ES; Gjyrezi A; Galletti G; Kim S; Worroll D; Stewart J; Zaher A; Szatrowski TP; Ballman KV; Kita K; Tasaki S; Bai Y; Portella L; Kirby BJ; Saad F; Eisenberger MA; Nanus DM; Giannakakou P
Clin Cancer Res; 2019 Mar; 25(6):1880-1888. PubMed ID: 30301829
[TBL] [Abstract][Full Text] [Related]
11. Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer.
Sharp A; Coleman I; Yuan W; Sprenger C; Dolling D; Rodrigues DN; Russo JW; Figueiredo I; Bertan C; Seed G; Riisnaes R; Uo T; Neeb A; Welti J; Morrissey C; Carreira S; Luo J; Nelson PS; Balk SP; True LD; de Bono JS; Plymate SR
J Clin Invest; 2019 Jan; 129(1):192-208. PubMed ID: 30334814
[TBL] [Abstract][Full Text] [Related]
12. Standardization of CTC AR-V7 PCR assay and evaluation of its role in castration resistant prostate cancer progression.
Tommasi S; Pilato B; Carella C; Lasorella A; Danza K; Vallini I; De Summa S; Naglieri E
Prostate; 2019 Jan; 79(1):54-61. PubMed ID: 30141201
[TBL] [Abstract][Full Text] [Related]
13. Androgen Receptor Variant AR-V9 Is Coexpressed with AR-V7 in Prostate Cancer Metastases and Predicts Abiraterone Resistance.
Kohli M; Ho Y; Hillman DW; Van Etten JL; Henzler C; Yang R; Sperger JM; Li Y; Tseng E; Hon T; Clark T; Tan W; Carlson RE; Wang L; Sicotte H; Thai H; Jimenez R; Huang H; Vedell PT; Eckloff BW; Quevedo JF; Pitot HC; Costello BA; Jen J; Wieben ED; Silverstein KAT; Lang JM; Wang L; Dehm SM
Clin Cancer Res; 2017 Aug; 23(16):4704-4715. PubMed ID: 28473535
[No Abstract] [Full Text] [Related]
14. Diverse AR-V7 cistromes in castration-resistant prostate cancer are governed by HoxB13.
Chen Z; Wu D; Thomas-Ahner JM; Lu C; Zhao P; Zhang Q; Geraghty C; Yan PS; Hankey W; Sunkel B; Cheng X; Antonarakis ES; Wang QE; Liu Z; Huang TH; Jin VX; Clinton SK; Luo J; Huang J; Wang Q
Proc Natl Acad Sci U S A; 2018 Jun; 115(26):6810-6815. PubMed ID: 29844167
[TBL] [Abstract][Full Text] [Related]
15. Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting.
Antonarakis ES; Armstrong AJ; Dehm SM; Luo J
Prostate Cancer Prostatic Dis; 2016 Sep; 19(3):231-41. PubMed ID: 27184811
[TBL] [Abstract][Full Text] [Related]
16. Targeting Androgen Receptor Activation Function-1 with EPI to Overcome Resistance Mechanisms in Castration-Resistant Prostate Cancer.
Yang YC; Banuelos CA; Mawji NR; Wang J; Kato M; Haile S; McEwan IJ; Plymate S; Sadar MD
Clin Cancer Res; 2016 Sep; 22(17):4466-77. PubMed ID: 27140928
[TBL] [Abstract][Full Text] [Related]
17. Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9
Wang R; Sun Y; Li L; Niu Y; Lin W; Lin C; Antonarakis ES; Luo J; Yeh S; Chang C
Eur Urol; 2017 Nov; 72(5):835-844. PubMed ID: 28528814
[TBL] [Abstract][Full Text] [Related]
18. Androgen receptor splice variants activating the full-length receptor in mediating resistance to androgen-directed therapy.
Cao B; Qi Y; Zhang G; Xu D; Zhan Y; Alvarez X; Guo Z; Fu X; Plymate SR; Sartor O; Zhang H; Dong Y
Oncotarget; 2014 Mar; 5(6):1646-56. PubMed ID: 24722067
[TBL] [Abstract][Full Text] [Related]
19. Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors.
Zhu Y; Dalrymple SL; Coleman I; Zheng SL; Xu J; Hooper JE; Antonarakis ES; De Marzo AM; Meeker AK; Nelson PS; Isaacs WB; Denmeade SR; Luo J; Brennen WN; Isaacs JT
Oncogene; 2020 Nov; 39(45):6935-6949. PubMed ID: 32989253
[TBL] [Abstract][Full Text] [Related]
20. Novel Junction-specific and Quantifiable In Situ Detection of AR-V7 and its Clinical Correlates in Metastatic Castration-resistant Prostate Cancer.
Zhu Y; Sharp A; Anderson CM; Silberstein JL; Taylor M; Lu C; Zhao P; De Marzo AM; Antonarakis ES; Wang M; Wu X; Luo Y; Su N; Nava Rodrigues D; Figueiredo I; Welti J; Park E; Ma XJ; Coleman I; Morrissey C; Plymate SR; Nelson PS; de Bono JS; Luo J
Eur Urol; 2018 May; 73(5):727-735. PubMed ID: 28866255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
